Showing results (141-150 of 162) with videos related to
Sort By:
Pageof 17
Science Translational Medicine|June 28, 2023
Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphomaCristina Mastini, Marco Campisi, Enrico Patrucco, et al.Cancer Discovery|October 7, 2021
Sex-Biased ZRSR2 Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and ApoptosisKatsuhiro Togami, Sun Sook Chung, Vikas Madan, et al.Blood Advances|May 30, 2024
Geographic EBV variants confound disease-specific variant interpretation and predict variable immune therapy responsesEdward L Briercheck, Shashidhar Ravishankar, Elshafa Hassan Ahmed, et al.Blood|October 15, 2021
A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomasAlison J Moskowitz, Paola Ghione, Eric Jacobsen, et al.The Lancet. Oncology|August 11, 2015
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registryAlessandro Pastore, Vindi Jurinovic, Robert Kridel, et al.Nature Genetics|April 22, 2014
Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylationAndrew A Lane, Bjoern Chapuy, Charles Y Lin, et al.Disaster Medicine and Public Health Preparedness|June 18, 2019
Chemical, Biological, Radiological, Nuclear, and Explosive (CBRNE) Science and the CBRNE Science Medical Operations Science Support Expert (CMOSSE)C Norman Coleman, Judith L Bader, John F Koerner, et al.Nature Medicine|June 17, 2024
Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trialSteven M Horwitz, Ajit J Nirmal, Jahan Rahman, et al.Cell Reports|April 25, 2020
Cathepsin S Alterations Induce a Tumor-Promoting Immune Microenvironment in Follicular LymphomaDeepak Bararia, Johannes A Hildebrand, Sebastian Stolz, et al.Science Translational Medicine|September 20, 2023
TP63 fusions drive multicomplex enhancer rewiring, lymphomagenesis, and EZH2 dependenceGongwei Wu, Noriaki Yoshida, Jihe Liu, et al.Pageof 17